How do you actually get enclomiphene?
No enclomiphene product is FDA approved or sold over the counter in the United States. The legitimate clinical route is an evaluation by a prescriber authorized under applicable state law and, if prescribed, patient-specific compounding and dispensing by a pharmacy authorized for the patient's state.3
A typical service collects a health history and laboratory results, then has a licensed clinician decide whether treatment is appropriate. If prescribed, a compounding pharmacy prepares the patient-specific product. State licensing, clinical criteria, pharmacy partners and follow-up differ, so the same platform may not offer the same product in every state.
A diagnosis of testosterone deficiency requires compatible symptoms or signs and consistently low testosterone, confirmed on two separate early-morning tests. The Endocrine Society specifies fasting samples; free testosterone is appropriate when total testosterone is borderline or a condition may alter sex hormone-binding globulin.12 LH and FSH then help distinguish primary from secondary hypogonadism. They inform whether a SERM mechanism is a reasonable fit, but no single result guarantees response. See who qualifies for enclomiphene.
Is enclomiphene legal?
No enclomiphene product is FDA approved. Repros reported receiving a Complete Response Letter in December 2015 and said FDA considered the submitted studies inadequate to demonstrate clinical benefit. Development stopped without approval.4 FDA's later scientific review likewise found hormone changes but insufficient evidence of clinically meaningful benefit.5
Enclomiphene citrate appears in FDA's Category 1, "bulk drug substances under evaluation." Under its interim policy, FDA generally does not intend to take action against qualifying 503A compounders solely over use of a Category 1 bulk substance when all policy conditions are met. That is conditional enforcement discretion, not FDA approval, a finding of safety or effectiveness, or a blanket legal safe harbor.67
FDA's Pharmacy Compounding Advisory Committee voted 8 to 4 against inclusion in June 2022, and FDA's briefing concluded that the criteria weighed against adding enclomiphene to the final bulks list.58 A final exclusion would remove the current Category 1 bulk-substance enforcement-discretion route. The timing and full legal effect depend on federal and state law, so this page does not claim that every current prescription is lawful or predict every route after a final decision. The contrast with the FDA-approved alternative is worth reading before you choose.
What about sites that sell it without a prescription?
Some sites label enclomiphene products for research use rather than dispensing a patient-specific prescription through a licensed pharmacy. A research-use label is not evidence that a product is suitable for human use, and it does not create prescriber or pharmacist accountability.
The practical difference is accountability. In the legitimate route, an authorized prescriber evaluates the patient and a licensed pharmacy dispenses the prescription. FDA has separately warned telehealth companies not to imply that compounded drugs are FDA approved or reviewed like approved products.9 FDA actions involving other drug classes do not prove the contents or legal status of a particular enclomiphene listing.
“If a site will sell it to you without a blood test, that is not a shortcut. It is the warning.”
How do you choose a provider?
Verify the process before paying. In a 2022 secret-shop study of seven direct-to-consumer testosterone therapy platforms, six offered therapy to a fictional patient with normal testosterone and none measured morning total testosterone on two separate occasions.10 The study did not evaluate enclomiphene providers, so it is a reason to ask specific questions, not a measured failure rate for this market. To see those questions applied to public pages, our Hims vs Maximus comparison walks two of the biggest programs through them.
Use public records where possible, then get the remaining answers in writing.
| What to check | How to verify | Record |
|---|---|---|
| Prescriber and pharmacy | Ask for both names, then check the prescriber in the state medical board and the pharmacy in the relevant board of pharmacy database | Verified publicly / ask / red flag |
| Diagnosis | Symptoms or signs plus two separate early-morning total testosterone results; ask whether fasting and free testosterone are relevant12 | Verified publicly / ask / red flag |
| Cause and treatment fit | LH and FSH interpreted after low testosterone is confirmed; free testosterone and further tests used when clinically indicated | Verified publicly / ask / red flag |
| Regulatory disclosure | A plain statement that the compounded drug is not FDA approved or reviewed before marketing for safety, effectiveness or quality | Verified publicly / ask / red flag |
| Cash at risk | Amount due today, total committed cash, labs, membership, shipping, early-exit and refund terms | Verified publicly / ask / red flag |
| Follow-up and safety | Written lab schedule, outcomes reviewed, adverse-event contact and urgent-care instructions | Verified publicly / ask / red flag |
A public page can verify only part of the service. Preserve screenshots or written answers for anything that affects cash or clinical follow-up, and compare them with the dated enclomiphene cost snapshot before checkout.
“Ask one question before you pay: the all-in cost of the first three months, labs included. A provider with a clean answer has nothing to bury.”
Is it available in every state?
Availability depends on the prescriber's state license, the pharmacy's authority to dispense or ship, provider policy and state-specific telehealth and compounding rules. Public state lists are often product specific, so a testosterone or add-on eligibility list should not be treated as an enclomiphene map.
Check eligibility for the exact product before paying. If one platform cannot serve the state, a locally authorized clinician and appropriately licensed pharmacy may be an alternative, but availability is not guaranteed.
What happens after you start?
Enclomiphene has no FDA-approved label that defines a standard monitoring schedule for men. The prescriber should state the baseline tests, follow-up timing, clinical outcomes and adverse-event plan. Current commercial examples differ: Maximus publishes baseline, month 1, month 3 and annual labs, while Hone publishes quarterly monitoring for its Plus non-TRT pathway.1112 Those are provider protocols, not consensus standards.
Enclomiphene has no approved safety label. The FDA-approved clomiphene label warns about visual symptoms and advises stopping treatment and prompt ophthalmologic evaluation; applying that warning to enclomiphene is a precautionary extrapolation from a closely related drug.13 Seek prompt clinical advice for new visual symptoms. FDA's enclomiphene review found hormone effects but insufficient evidence of clinically meaningful symptom benefit and identified thromboembolic, cardiovascular and laboratory safety signals.5
Common questions
Do you need a prescription for enclomiphene?
No enclomiphene product is FDA approved or sold over the counter in the United States.
The legitimate clinical route is an evaluation by an appropriately licensed prescriber and, if prescribed, patient-specific compounding and dispensing by a pharmacy authorized for the patient's state.
Can your regular doctor prescribe enclomiphene?
A prescriber authorized under applicable state law may choose to prescribe patient-specific compounded enclomiphene, and the dispensing pharmacy must be authorized for the patient's state.
A clinician can also decline because enclomiphene is not FDA approved or is not clinically appropriate.
How do you check a compounding pharmacy?
Ask for the dispensing pharmacy's name before paying, then confirm its license and status with the relevant state board of pharmacy.
Also verify that the prescriber is licensed in your state, that the prescription is patient specific, and that the service explains follow-up and adverse-event contact.
Does the FDA send warning letters about enclomiphene?
We did not locate an enclomiphene-specific FDA warning letter in the sources reviewed through 21 August 2026, but that is not proof none exists.
FDA tells telehealth companies not to imply that compounded drugs are FDA approved or reviewed like approved products.
References
- 1.Bhasin S, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2018;103(5):1715-1744. doi:10.1210/jc.2018-00229.
- 2.Mulhall JP, et al. Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology. 2018;200(2):423-432. doi:10.1016/j.juro.2018.03.115.
- 3.US Food and Drug Administration. Compounding and the FDA: Questions and Answers; bulk drug substances used in compounding under section 503A. Current pages accessed 21 August 2026.
- 4.Repros Therapeutics Inc. Annual report, Form 10-K for fiscal year 2015. US Securities and Exchange Commission, filed 14 March 2016.
- 5.US Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing document: Enclomiphene Citrate. 8 June 2022.
- 6.US Food and Drug Administration. Category 1 bulk drug substances under evaluation. Updated 14 May 2026; accessed 21 August 2026.
- 7.US Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Final Guidance for Industry, January 2025.
- 8.US Food and Drug Administration. Minutes of the 8 June 2022 Pharmacy Compounding Advisory Committee meeting. Approved 19 August 2022.
- 9.US Food and Drug Administration. FDA to telehealth companies: what to know when promoting compounded drugs. June 2026; accessed 21 August 2026.
- 10.Dubin JM, et al. Guideline-discordant care among direct-to-consumer testosterone therapy platforms. JAMA Internal Medicine. 2022;182(12):1321-1323. doi:10.1001/jamainternmed.2022.4928.
- 11.Maximus. Lab Testing Costs and Policies and Lab Testing Overview. Accessed 21 August 2026.
- 12.Hone Health. Men's Plus HRT Lab Testing Schedule for Clomiphene and Non-TRT Therapies. Accessed 21 August 2026.
- 13.US National Library of Medicine. Clomiphene citrate tablets, FDA-approved prescribing information. DailyMed, current label accessed 21 August 2026.
This article is for general education and is not medical advice, a diagnosis, or a treatment recommendation. It does not create a clinician and patient relationship. Talk to a licensed clinician about your own situation, and call your doctor or 911 for anything urgent.